Holen Sie sich die Stockscreener-App
1.09
0.00%
0.00
Schlusskurs vom Vortag:
$1.09
Offen:
$1.09
24-Stunden-Volumen:
243.99K
Relative Volume:
0.34
Marktkapitalisierung:
$65.88M
Einnahmen:
$3.82M
Nettoeinkommen (Verlust:
$-51.89M
KGV:
-0.8583
EPS:
-1.27
Netto-Cashflow:
$-39.52M
1W Leistung:
-27.33%
1M Leistung:
-35.12%
6M Leistung:
-42.18%
1J Leistung:
-54.20%
1-Tages-Spanne:
$1.02
$1.095
1-Wochen-Bereich:
$1.02
$1.5599
52-Wochen-Spanne:
$0.45
$3.2491
Cue Biopharma Inc Stock (CUE) Company Profile
Firmenname
Cue Biopharma Inc
Sektor
Branche
Telefon
617-949-2680
Adresse
40 GUEST STREET, BOSTON, MA
Vergleichen Sie CUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CUE | 1.09 | 65.88M | 3.82M | -51.89M | -39.52M | -1.27 |
| VRTX | 450.35 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.65 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.57 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.09 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-11-21 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-03 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-04-09 | Eingeleitet | Stifel | Buy |
| 2020-01-28 | Eingeleitet | BTIG Research | Buy |
| 2020-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Cue Biopharma’s Nasdaq Compliance Struggle: Risks and Implications for Future Stability - MSN
Jefferies cuts Cue Biopharma shares target, retains buy rating on potential - Investing.com UK
Cue Biopharma earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Cue Biopharma Inc (CUE) Quarterly 10-Q Report - Quartz
Cue names Daniel Baker interim CDO, CSO Anish Suri to transition to advisor role - MSN
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses - TipRanks
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Cue Biopharma Inc (CUE) Q3 2024 Earnings: EPS of $0.17 Beats Est - GuruFocus.com
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Cue Biopharma's Cancer Drug Shows 91% Survival Rate in Phase 1 Trial, Revenue Up 57% | CUE Stock News - StockTitan
Cue Biopharma Announces Strategic Organizational Transition - GlobeNewswire
Cue Biopharma Strengthens Leadership: J&J Veteran with 15+ Drug Approvals Joins as CDO | CUE Stock News - StockTitan
Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus reshapes outlook - Investing.com Australia
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference - The Manila Times
Cue Biopharma to Present Latest Clinical Trial Data at Stifel Healthcare Conference | CUE Stock News - StockTitan
Cue Biopharma Presents Positive Updated Data from its Phase - GlobeNewswire
Cue Biopharma Cancer Drug Trial Soars: 91% Survival Rate, Shatters Expectations | CUE Stock News - StockTitan
Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update - MarketBeat
Cue Biopharma authorizes more shares By Investing.com - Investing.com Australia
Cue Biopharma authorizes more shares - Investing.com India
There is no doubt that Cue Biopharma Inc (CUE) ticks all the boxes. - SETE News
Market Watch: Cue Biopharma Inc (CUE)’s Noteworthy Drop, Closing at 1.23 - The Dwinnex
Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89% - Yahoo Finance
Technical analysis of Cue Biopharma Inc (CUE) stock chart patterns - US Post News
Cue Biopharma stock rallies nearly 40% on upcoming presentations - MSN
Cue Biopharma amends loan agreement, easing cash requirements - Investing.com India
Cue Biopharma amends loan agreement, easing cash requirements By Investing.com - Investing.com UK
Cue Biopharma Announces Upcoming Scientific Presentations - GlobeNewswire
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - StockTitan
Quarterly Snapshot: Quick and Current Ratios for Cue Biopharma Inc (CUE) - The Dwinnex
Biotech layoff tracker: 13 biotechs cut over 1,400 jobs - The Business Journals
Views of Wall Street’s Leading Experts on Cue Biopharma Inc - SETE News
What to expect from Cue Biopharma Inc’s (CUE) current quarter earnings? - US Post News
Cue Biopharma Inc (CUE) Stock: A Year of Highs and Lows - The InvestChronicle
Form 424B5 Cue Biopharma, Inc. - StreetInsider.com
SEC Form 424B5 filed by Cue Biopharma Inc. - Quantisnow
Wall Street SWOT: Cue Biopharma stock pivots to autoimmune focus amid restructuring - Investing.com India
Cue biopharma announces proposed public offering - MSN
Cue Biopharma prices $12M stock offering - MSN
Cue Biopharma Prices of $12.0 Million Public Offering - citybiz
Cue Biopharma Announces Pricing of $12.0 Million Public Offering - StockTitan
Cue Biopharma Announces Proposed Public Offering - The Bakersfield Californian
Cue Biopharma launches public stock offering By Investing.com - Investing.com Australia
Cue Biopharma launches public stock offering - Investing.com
Finanzdaten der Cue Biopharma Inc-Aktie (CUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):